Japan’s Shionogi & Co has received approval from the U.S. Food and Drug Administration (FDA) for its oral antiviral Ensitrelvir, marketed as Xocova, as a preventive treatment for people who have been exposed to COVID-19. The decision makes Xocova the first FDA‐approved oral option shown in clinical trials to help prevent symptomatic COVID-19 after exposure, [...]